On October 22–23, 2026, the Hotel Parque Central will host the “Workshop on Biosimilars: Innovation and Access in Healthcare,” organized by the import-export company FARMACUBA, the entity announced.

RELATED:

Cuban Sciences Academy Awards Prize for Regenerative Medicine Research

Over the course of two days, specialists and institutions from the biotechnology, pharmaceutical, and healthcare sectors will share experiences regarding the introduction, regulation, clinical evaluation, commercialization, and medical applications of biosimilars in Cuba.

The program includes panels on the policy, introduction, and final processing of biosimilars in Cuba; commercialization and promotion strategies; as well as regulatory aspects, clinical evaluation, and the medical applications of these products.

FARMACUBA will present information on the biosimilars for which it holds the rights, and will discuss market opportunities and economic benefits linked to their development and commercialization. The event will also provide an opportunity to establish connections with Cuban representative offices abroad, embassies, and potential international clients.

Ver esta publicación en Instagram

Una publicación compartida por Empresa FARMACUBA (@_farmacuba_)

Presentation of Rituximab

A key highlight will be the official presentation of Rituximab, identified as the first biosimilar to undergo final processing in Cuban biopharmaceutical facilities. During the workshop, its regulatory and clinical outcomes, medical applications, and aspects related to its introduction and commercialization within the National Health System will be presented.

The second day will feature interactive virtual meetings with Cuban representatives abroad, embassies, and prospective foreign buyers. This initiative aims to promote the international reach of biosimilars developed under the auspices of FARMACUBA.

Additionally, a catalog of biosimilars will be presented, and the role of Rituximab in the treatment of B-cell lymphomas will be examined.

The workshop will serve as a forum for exchange among national and international specialists, intended to expand knowledge, explore avenues for collaboration, and examine new alternatives for the development and commercialization of biosimilars in Cuba.

FARMACUBA

Facilitator in the introduction and commercialization of biosimilars, strengthening the link between pharmaceutical innovation and national healthcare.

As an importer, exporter, distributor, and marketer of pharmaceutical products, the company is part of the BioCubaFarma business group, which operates under the Council of Ministers of the Republic of Cuba.

It ensures the provision of necessary resources to the Cuban pharmaceutical industry, while also managing the export of medicines and technical services to international clients.

In line with the country’s new economic and commercial strategy—designed to boost the development of the business sector—FARMACUBA aims to set a benchmark both domestically and internationally within the pharmaceutical industry. This presents a unique opportunity to expand knowledge, forge strategic alliances, and explore new avenues for collaboration.

From teleSUR English via This RSS Feed.